


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+6.09%
-4.41%
+4.44%
+4.40%
-8.21%
RARE
Ultragenyx Pharmaceu
$24.31
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Trading below its fair value

Investors confidence is positive
RARE Price Performance
$34.19 (-28.90%)
$34.59 (-29.72%)
$32.03 (-24.10%)
$44.78 (-45.71%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a weak earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
RARE Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
RARE Street Sentiment is bullish and have positive views on the near-term outlook
RARE has Low risk level

Average key support and resistance price levels
RARE
Ultragenyx Pharmaceu
24.31
+0.41%
CTGO
Contango ORE Inc.
31.70
-3.32%
RVYL
Ryvyl Inc.
5.69
-9.83%
AVO
Mission Produce
13.57
+0.82%
NVDA
NVIDIA
186.47
-0.64%
What is RARE current stock price?
What are RARE stock strengths?
What is RARE Risk Level?
What is RARE market cap and volume?
What is RARE current Stock IQ?
Should I buy RARE stock right now?
Is RARE a Strong Buy right now?
What does a 'Strong Buy' rating mean for RARE?
What does a 'Strong Sell' rating mean for RARE?
What factors influence RARE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+6.09%
-4.41%
+4.44%
+4.40%
-8.21%
RARE
Ultragenyx Pharmaceu
Current Price
$24.31
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Trading below its fair value

Investors confidence is positive
Recently Viewed
RARE
Ultragenyx Pharmaceu
24.31
+0.41%
CTGO
Contango ORE Inc.
31.70
-3.32%
RVYL
Ryvyl Inc.
5.69
-9.83%
AVO
Mission Produce
13.57
+0.82%
NVDA
NVIDIA
186.47
-0.64%

RARE Price Performance
$34.19 (-28.90%)
$34.59 (-29.72%)
$32.03 (-24.10%)
$44.78 (-45.71%)
RARE Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a weak earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
RARE Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
RARE Street Sentiment is bullish and have positive views on the near-term outlook
RARE has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Dec 11, 2025
Reiterate
Buy
Citi
Nov 25, 2025
Reiterate
Overweight
Barclays
Nov 06, 2025
Reiterate
Buy
TD Cowen
Sep 30, 2025
Reiterate
Buy
Cantor Fitzgerald
RARE Stock IQ
RARE Latest Analysis
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). NOVATO Calif. Jan. 23 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases today reported the grant of 16355 restricted stock units of the companys common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of t
Fri Jan 23, 2026
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Mon Jan 12, 2026
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery.
Mon Jan 12, 2026
Analysts Lower Ultragenyx (RARE) Target but Stay ish. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 6 H.C. Wainwright reduced its price target on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from $80 to $60 but kept its Buy rating on the stock. The reduced price target still represents a significant upside from [….]
Fri Jan 9, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
RARE Stock trends
RARE Stock performance
RARE Stock analysis
RARE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.